Research Progress of Protective Effects and Mechanism of Mangiferin on Myocardial Remodeling_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZOUShu-fan ,  CHENLin

Institute of Cardiovascular surgery, Xinqiao Hospital of Third Military Medical University, Chongqing 400037, P. R. China;

Corresponding?author：

CHENLin, Email: chenlin_xq@yahoo.com.cn

Keywords：

Mangiferin; Myocardial infarction; Pressure overload; p38 mitogen activated protein kinases; Myocardial remodeling

DOI：

10.7507/1007-4848.20150218

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Myocardial remodeling is one of the important pathological basis when myocardial infarction or pressure overload occurs, whereas mangiferin which is a naturally occurring xanthone has a broad range of therapeutic effect on postinfarction myocardial remodeling. Mangiferin attenuates myocardial infarction by preventing the accumulation of myocardial collagen and the development of intercellular fibrosis. Mangiferin's inhibition to p38 mitogen activated protein kinases plays an important role in the cardioprotective effect. Inhibition of p38 mitogen activated protein kinases significantly decreases TNF-α and then brings the cardioprotective effect. Similarly, p38 mitogen activated protein kinases in pressure overload disease also play a very important role. Understanding of these has direct implications for clinical therapy.

Citation： ZOUShu-fan, CHENLin. Research Progress of Protective Effects and Mechanism of Mangiferin on Myocardial Remodeling. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2015, 22(9): 875-878. doi: 10.7507/1007-4848.20150218 Copy

1.	Solomon SD, Shin SH, Sh ah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with systolic dysfunction. Eur Heart J, 2011, 32(10):1227-1234.
2.	Zhu M, Feng J, Lucchinetti E, et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res, 2006, 72(1):152-162.
3.	Opie LH, Commerford PJ, Gersh BJ, et al. Controversies in ventricular remodeling. Lancet, 2006, 367(9507):356-367.
4.	何飛, 曾憲彪, 韋桂寧, 等. 芒果苷利膽作用及對膽囊平滑肌痙攣的影響. 中國藥師, 2014, 17(7):1083-1085.
5.	胡文姬, 李學堅, 劉布鳴, 等. 芒果苷苷元研究進展. 時珍國醫國藥, 2013, 24(11):2759-2763.
6.	Amazzal L, Lap?tre A, Quignon F, et al. Mangiferin protects against 1-methyl-4-phenylpyridinium toxicity mediated by oxidative stress in N2A cells. Neurosci Lett, 2007, 418(2):159-164.
7.	He L, Peng X, Zhu J, et al. Mangiferin attenuate sepsis-induced acute kidney injury via antioxidant and anti-inflammatory effects. Am J Nephrol, 2014, 40(5):441-450.
8.	Lai L, Lin LC, Lin JH, et al. Pharmacokinetic study of freemangiferin in rats by microdialysis coupled with microbore high-performance liquid chromatography and tandem mass spectrometry. J Chromatogr A, 2003, 987(1-2):367-374.
9.	Arozal W, Suyatna FD, Juniantito V, et al. The effects of mangiferin(Mangifera indica L) in doxorubicin-induced cardiotoxicity in rats. Drug Res(Stuttg), 2014.[Epub ahead of print].
10.	Nair PS, Shyamala Devi CS. Efficacy of mangiferin on serum and heart tissue lipids in rats subjected to isoproterenol induced cardiotoxicity. Toxicol, 2006, 228(2-3):135-139.
11.	Gottlieb M, Leal-Campanario R, Campos-Esparza MR, et al. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. Neurobio Disease, 2006, 23(2):374-386.
12.	Beltrán AE, Alvarez Y, Xavier FE, et al. Vascular effects of the Mangifera indica L. extract(Vimang). Eur J Pharmacol, 2004, 499(3):297-305.
13.	洪永福. 韓公羽, 郭學敏. 西陵知母中新芒果苷的分離與結構鑒定. 藥學學報, 1997, 32(6):473-475.
14.	Das J, Ghosh J, Roy A, et al. Mangiferin exerts hepatoprotective activity against D-galactosamine induced acute toxicity and oxidative/nitrosative stress via Nrf2-NFκB pathways. Toxicol Appl Pharmacol, 2012, 260(1):35-47.
15.	Hou J, Zheng D, Fan K, et al. Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats. Pharmacology, 2012, 90(3-4):177-182.
16.	Prabhu S, Jainu M, Sabitha KE, et al. Effect of mangiferin on mitochondrial energy production in experimentally induced myocardial infarcted rats. Vasc Pharmacol, 2006, 44(6):519-525.
17.	Yin HQ, Wang B, Zhang JD, et al. Effect of traditional Chinese medicine Shu-Mai-Tang on attenuating TNF alpha-induced myocardial fibrosis in myocardial ischemia rats. J Ethnopharmacol, 2008, 118(1):133-139.
18.	Liao P, Georgakopoulos D, Kovacs A, et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA, 2001, 98(21):12283-12288.
19.	Matsumoto-Ida M, Takimoto Y, Aoyama T, et al. Activation of TGFbeta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol, 2006, 290(2):709-715.
20.	Zhou L, Azfer A, Niu J, et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res, 2006, 98(9):1177-1185.
21.	Li M, Georgakopoulos D, Lu G, et al. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation, 2005, 111(19):2494-2502.
22.	Leenders JJ, Wijnen WJ, Hiller M, et al. Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity. J Biol Chem, 2010, 285(35):27449-27456.
23.	Laskarin G, Zaputovic L, Persic V, et al. Harmful immune reactions during acute myocardial infarction. Med Hypotheses, 2012, 78(6):703-706.
24.	Roy SJ, Stanely Mainzen Prince P. Protective effects of sinapic acid on lysosomal dysfunction in isoproterenol induced myocardial infarcted rats. Food Chem Toxicol 2012, 50(11):3984-3989.
25.	Punithavathi VR, Prince PS. Pretreatment with a combination of quercetin and alpha-tocopherol ameliorates adenosine triphosphatases and lysosomal enzymes in myocardial infarcted rats. Life Sci, 2010, 86(5-6):178-184.
26.	Prabhu S, Jainu M, Sabitha KE, et al. Cardioprotective effect of mangiferin on isoproterenol induced myocardial infarction in rats. Indian J Exp Biol, 2006, 44(3):209-215.
27.	Prabhu S, Narayan S, Devi CS. Mechanism of protective action of mangiferin on suppression of inflammatory response and lysosomal instability in rat model of myocardial infarction. Phytother Res, 2009, 23(6):756-760.
28.	Studholme DJ, Buck M. The biology of enhancer-dependent transcriptional regulation in bacteria:insights from genome sequences. FEMS Microbiol Lett, 2000, 186(1):1-9.
29.	Vu TH, Werb Z. Matrix metalloproteinases:effectors of development and normal physiology. Genes Dev, 2000, 14(17):2123-2133.
30.	Van Linthout S, Seeland U, Riad A, et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol, 2008, 103(4):319-327.
31.	Wang X, Lv H, Gu Y, et al. Protective effect of lycopene on cardiac function and myocardial fibrosis after acute myocardial infarction in rats via the modulation of p38 and MMP-9. J Mol Histol, 2014, 45(1):113-120.
32.	Slavic S, Lauer D, Sommerfeld M, et al. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. J Mol Med(Berl), 2013, 91(7):811-823.
33.	Jung JS, Jung K, Kim DH, et al. Selective inhibition of MMP-9 gene expression by mangiferin in PMA-stimulated human astroglioma cells:involvement of PI3K/Akt and MAPK signaling pathways. Pharmacol Res, 2012, 66(1):95-103.
34.	Hou J, Zheng D, Zhong G, et al. Mangiferin mitigates diabetic cardiomyopathy in streptozotocin-diabetic rats. Can J Physiol Pharmacol, 2013, 91(9):759-763.
35.	Shen JG, Quo XS, Jiang B, et al. Chinonin, a novel drug against cardiomyocyte apoptosis induced by hypoxia and reoxygenation. Biochim Biophys Acta, 2000, 1500(2):217-226.
36.	Abdel-Latif AM, Abuel-Ela HA, El-Shourbagy SH. Increased caspase-3 and altered expression of apoptosis-associated proteins, Bcl-2 and Bax in lichen planus. Clin Exp Dermatol, 2009, 34(3):390-395.
37.	Foster CR, Daniel LL, Daniels CR, et al. Deficiency of ataxia telangiectasia mutated kinase modulates cardiac remodeling following myocardial infarction:involvement in fibrosis and apoptosis. PLoS One, 2013, 8(12):e83513.
38.	Zheng D, Hou J, Xiao Y, et al. Cardioprotective effect of mangiferin on left ventricular remodeling in rats. Pharmacology, 2012, 90(1-2):78-87.
39.	Frantz S, Tillmanns J, Kuhlencordt PJ, et al. Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemiareperfusion injury. Am J Pathol, 2008, 171(2):507-512.
40.	Cacciapaglia F, Salvatorelli E, Minotti G, et al. Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha:brief insight into a beneficial paradox. Cardiovasc Toxicol, 2014, 14(4):387-392.
41.	Li MH, Zhang YJ, Yu YH, et al. Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. Eur J Pharmacol, 2014, 7(28):67-76.
42.	Liao Y, Bin J, Luo T, et al. CB1 cannabinoid receptor deficiency promotes cardiac remodeling induced by pressure overload in mice. Int J Cardiol, 2013, 167(5):1936-1944.
43.	張青, 王志祥, 宋立丹, 等. 響應曲面法優化超聲提取芒果葉中芒果苷的工藝研究. 西北藥學雜志, 2014, 29(3):237-241.
44.	姚風艷, 孫連娜. 芒果苷藥理作用及其結構修飾的研究進展. 中國實驗方劑學雜志, 2014, 20(12):248-252.

1. Solomon SD, Shin SH, Sh ah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with systolic dysfunction. Eur Heart J, 2011, 32(10):1227-1234.
2. Zhu M, Feng J, Lucchinetti E, et al. Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res, 2006, 72(1):152-162.
3. Opie LH, Commerford PJ, Gersh BJ, et al. Controversies in ventricular remodeling. Lancet, 2006, 367(9507):356-367.
4. 何飛, 曾憲彪, 韋桂寧, 等. 芒果苷利膽作用及對膽囊平滑肌痙攣的影響. 中國藥師, 2014, 17(7):1083-1085.
5. 胡文姬, 李學堅, 劉布鳴, 等. 芒果苷苷元研究進展. 時珍國醫國藥, 2013, 24(11):2759-2763.
6. Amazzal L, Lap?tre A, Quignon F, et al. Mangiferin protects against 1-methyl-4-phenylpyridinium toxicity mediated by oxidative stress in N2A cells. Neurosci Lett, 2007, 418(2):159-164.
7. He L, Peng X, Zhu J, et al. Mangiferin attenuate sepsis-induced acute kidney injury via antioxidant and anti-inflammatory effects. Am J Nephrol, 2014, 40(5):441-450.
8. Lai L, Lin LC, Lin JH, et al. Pharmacokinetic study of freemangiferin in rats by microdialysis coupled with microbore high-performance liquid chromatography and tandem mass spectrometry. J Chromatogr A, 2003, 987(1-2):367-374.
9. Arozal W, Suyatna FD, Juniantito V, et al. The effects of mangiferin(Mangifera indica L) in doxorubicin-induced cardiotoxicity in rats. Drug Res(Stuttg), 2014.[Epub ahead of print].
10. Nair PS, Shyamala Devi CS. Efficacy of mangiferin on serum and heart tissue lipids in rats subjected to isoproterenol induced cardiotoxicity. Toxicol, 2006, 228(2-3):135-139.
11. Gottlieb M, Leal-Campanario R, Campos-Esparza MR, et al. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. Neurobio Disease, 2006, 23(2):374-386.
12. Beltrán AE, Alvarez Y, Xavier FE, et al. Vascular effects of the Mangifera indica L. extract(Vimang). Eur J Pharmacol, 2004, 499(3):297-305.
13. 洪永福. 韓公羽, 郭學敏. 西陵知母中新芒果苷的分離與結構鑒定. 藥學學報, 1997, 32(6):473-475.
14. Das J, Ghosh J, Roy A, et al. Mangiferin exerts hepatoprotective activity against D-galactosamine induced acute toxicity and oxidative/nitrosative stress via Nrf2-NFκB pathways. Toxicol Appl Pharmacol, 2012, 260(1):35-47.
15. Hou J, Zheng D, Fan K, et al. Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats. Pharmacology, 2012, 90(3-4):177-182.
16. Prabhu S, Jainu M, Sabitha KE, et al. Effect of mangiferin on mitochondrial energy production in experimentally induced myocardial infarcted rats. Vasc Pharmacol, 2006, 44(6):519-525.
17. Yin HQ, Wang B, Zhang JD, et al. Effect of traditional Chinese medicine Shu-Mai-Tang on attenuating TNF alpha-induced myocardial fibrosis in myocardial ischemia rats. J Ethnopharmacol, 2008, 118(1):133-139.
18. Liao P, Georgakopoulos D, Kovacs A, et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA, 2001, 98(21):12283-12288.
19. Matsumoto-Ida M, Takimoto Y, Aoyama T, et al. Activation of TGFbeta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol, 2006, 290(2):709-715.
20. Zhou L, Azfer A, Niu J, et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res, 2006, 98(9):1177-1185.
21. Li M, Georgakopoulos D, Lu G, et al. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation, 2005, 111(19):2494-2502.
22. Leenders JJ, Wijnen WJ, Hiller M, et al. Regulation of cardiac gene expression by KLF15, a repressor of myocardin activity. J Biol Chem, 2010, 285(35):27449-27456.
23. Laskarin G, Zaputovic L, Persic V, et al. Harmful immune reactions during acute myocardial infarction. Med Hypotheses, 2012, 78(6):703-706.
24. Roy SJ, Stanely Mainzen Prince P. Protective effects of sinapic acid on lysosomal dysfunction in isoproterenol induced myocardial infarcted rats. Food Chem Toxicol 2012, 50(11):3984-3989.
25. Punithavathi VR, Prince PS. Pretreatment with a combination of quercetin and alpha-tocopherol ameliorates adenosine triphosphatases and lysosomal enzymes in myocardial infarcted rats. Life Sci, 2010, 86(5-6):178-184.
26. Prabhu S, Jainu M, Sabitha KE, et al. Cardioprotective effect of mangiferin on isoproterenol induced myocardial infarction in rats. Indian J Exp Biol, 2006, 44(3):209-215.
27. Prabhu S, Narayan S, Devi CS. Mechanism of protective action of mangiferin on suppression of inflammatory response and lysosomal instability in rat model of myocardial infarction. Phytother Res, 2009, 23(6):756-760.
28. Studholme DJ, Buck M. The biology of enhancer-dependent transcriptional regulation in bacteria:insights from genome sequences. FEMS Microbiol Lett, 2000, 186(1):1-9.
29. Vu TH, Werb Z. Matrix metalloproteinases:effectors of development and normal physiology. Genes Dev, 2000, 14(17):2123-2133.
30. Van Linthout S, Seeland U, Riad A, et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol, 2008, 103(4):319-327.
31. Wang X, Lv H, Gu Y, et al. Protective effect of lycopene on cardiac function and myocardial fibrosis after acute myocardial infarction in rats via the modulation of p38 and MMP-9. J Mol Histol, 2014, 45(1):113-120.
32. Slavic S, Lauer D, Sommerfeld M, et al. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. J Mol Med(Berl), 2013, 91(7):811-823.
33. Jung JS, Jung K, Kim DH, et al. Selective inhibition of MMP-9 gene expression by mangiferin in PMA-stimulated human astroglioma cells:involvement of PI3K/Akt and MAPK signaling pathways. Pharmacol Res, 2012, 66(1):95-103.
34. Hou J, Zheng D, Zhong G, et al. Mangiferin mitigates diabetic cardiomyopathy in streptozotocin-diabetic rats. Can J Physiol Pharmacol, 2013, 91(9):759-763.
35. Shen JG, Quo XS, Jiang B, et al. Chinonin, a novel drug against cardiomyocyte apoptosis induced by hypoxia and reoxygenation. Biochim Biophys Acta, 2000, 1500(2):217-226.
36. Abdel-Latif AM, Abuel-Ela HA, El-Shourbagy SH. Increased caspase-3 and altered expression of apoptosis-associated proteins, Bcl-2 and Bax in lichen planus. Clin Exp Dermatol, 2009, 34(3):390-395.
37. Foster CR, Daniel LL, Daniels CR, et al. Deficiency of ataxia telangiectasia mutated kinase modulates cardiac remodeling following myocardial infarction:involvement in fibrosis and apoptosis. PLoS One, 2013, 8(12):e83513.
38. Zheng D, Hou J, Xiao Y, et al. Cardioprotective effect of mangiferin on left ventricular remodeling in rats. Pharmacology, 2012, 90(1-2):78-87.
39. Frantz S, Tillmanns J, Kuhlencordt PJ, et al. Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemiareperfusion injury. Am J Pathol, 2008, 171(2):507-512.
40. Cacciapaglia F, Salvatorelli E, Minotti G, et al. Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha:brief insight into a beneficial paradox. Cardiovasc Toxicol, 2014, 14(4):387-392.
41. Li MH, Zhang YJ, Yu YH, et al. Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. Eur J Pharmacol, 2014, 7(28):67-76.
42. Liao Y, Bin J, Luo T, et al. CB1 cannabinoid receptor deficiency promotes cardiac remodeling induced by pressure overload in mice. Int J Cardiol, 2013, 167(5):1936-1944.
43. 張青, 王志祥, 宋立丹, 等. 響應曲面法優化超聲提取芒果葉中芒果苷的工藝研究. 西北藥學雜志, 2014, 29(3):237-241.
44. 姚風艷, 孫連娜. 芒果苷藥理作用及其結構修飾的研究進展. 中國實驗方劑學雜志, 2014, 20(12):248-252.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research Progress of Protective Effects and Mechanism of Mangiferin on Myocardial Remodeling

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content